Certificate of Competence: Premises and Personnel Requirements in Ethiopia
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Certificate of Competence (CoC) is Ethiopia’s authorization of an establishment, not of a product, issued by EFDA through the i-License module of eRIS. It has two legal anchors: Article 23(1) of Proclamation No. 1112/2019 (establishments carrying out the relevant activities must obtain a license), and item 9.2.3(h) of EFDA-GDL-046 (an agent handling imports on behalf of a manufacturer must hold the Ministry of Trade license and an EFDA-issued CoC at the time of import). The regulatory triangle is strict: the product needs an MA, the entity needs a CoC, and each consignment needs an import permit; no line of the triangle can be missing. One caution applies throughout this article: regarding specific technical conditions for the CoC, such as premises area, dedicated staffing levels, cold chain and temperature-humidity monitoring facilities, the publicly verifiable authoritative texts (Directive No. 872/2022 and its accompanying checklists) could not be obtained in full during this verification round, so every dimension involving specific technical parameters below is marked as a practical estimate, and companies must follow the CoC application requirements and on-site inspection checklists currently published by EFDA.
2. Legal basis
| Instrument | Reference number | Publication date | Provisions |
|---|---|---|---|
| Food and Medicine Administration Proclamation | Proclamation No. 1112/2019 | February 2019 | Article 23(1) |
| Food and Medicine Administration Proclamation | Proclamation No. 1112/2019 | February 2019 | Article 20(1) (10 categories of activities) |
| General Guideline for Market Authorization of Medical Devices | EFDA-GDL-046 (Fourth Edition) | January 2022 | Section 9.2.3(h) |
| General Guideline for Market Authorization of Medical Devices | EFDA-GDL-046 (Fourth Edition) | January 2022 | Annex IV (requirement to submit a scanned PDF of the CoC) |
| Medical Devices Import, Export and Wholesale Directive | Directive No. 872/2022 | 2022 | Specific premises and personnel conditions subject to the current official text |
3. Expert insights
Insight 1: The CoC binds the person, the MA binds the thing, and the two are constantly conflated.
Many companies read the fact that a product is registered as permission to handle the import themselves, overlooking the independent licensing requirement for establishments under Article 23(1). If the importing entity is not a licensed agent, or if the agent’s CoC has expired, the goods will still be stopped at the port even though the product MA is fully valid. The two authorizations are examined by different officers, at different nodes, against different criteria, and neither substitutes for the other. This separation is the structural reason why import planning in Ethiopia must be built around entities as well as products.
Insight 2: The judging point for the CoC is embedded in the agency agreement conditions, with contractual knock-on effects.
Item 9.2.3(h) makes holding the CoC at the time of import one of the eight conditions of the agency agreement. A missing CoC is therefore not merely a customs problem: it renders the agency agreement itself non-compliant with EFDA’s conditions, which in turn undermines the validity of the registration application built on that agreement. A single expired certificate can thus cascade backwards through the entire authorization chain, which is why CoC renewal dates deserve the same calendar discipline as MA expiry dates.
Insight 3: The submission form for the CoC has already been standardized.
Under the instructions of Annex IV of EFDA-GDL-046, the agency agreement submission must be accompanied by a valid scanned PDF of the CoC. This shows the CoC has entered the online verification chain of eRIS; the paper copy is no longer the sole credential, but it also means the certificate status must be retrievable in the system. If a paper certificate exists but the electronic record is not current, the verification chain breaks at exactly the point where the authority checks it.
Insight 4: The practical inspection dimensions (practical estimate, subject to the current official documents).
EFDA’s on-site attention to warehousing and trading establishments typically concentrates on: whether the business premises are independent and separated from non-business activities; whether dedicated technical personnel with the relevant professional background are in place; whether storage conditions and temperature-humidity monitoring are matched to the product range handled; whether traceable purchase and sales records are maintained; and whether the responsibilities of the quality manager are documented in writing. These are the industry’s common preparation directions; the specific items and judging criteria must follow the CoC application requirements and on-site inspection checklists currently published by EFDA.
4. Practical recommendations
- Fix the entity before fixing the product: before starting the MA application, confirm the local agent’s CoC status and that its business scope covers the device category.
- Put the CoC validity period into the import calendar: CoC and MA expiry dates do not coincide, so separate early-warning reminders must be set for each.
- Self-inspect along four lines: people, premises, records, temperature (practical estimate): appointment documents for dedicated technical staff, floor plans and premises independence, purchase and sales record ledgers, and temperature-humidity monitoring with deviation-handling records.
- Prepare the authorization chain for foreign entities: the power of attorney and the agency agreement under which the foreign manufacturer authorizes the local agent must be consistent with the entity named on the CoC.
- Obtain the official checklist early: request the current CoC application requirements and inspection checklist directly from EFDA or a local adviser, rather than importing checklists from other markets that may not match Ethiopian practice.
- Verify the electronic record, not just the paper: confirm the CoC appears correctly in eRIS before any submission that references it.
5. Verification checklist
- □ Confirmed that the importing / trading entity must hold a CoC (Article 23(1))
- □ The agency agreement satisfies the condition of item 9.2.3(h)
- □ The current EFDA CoC application requirements and on-site inspection checklist have been obtained
- □ Premises independence and layout meet the checklist requirements (practical estimate)
- □ Appointment and qualification documents for dedicated technical personnel are complete (practical estimate)
- □ Temperature-humidity monitoring and storage facilities are in place with records (practical estimate)
- □ Purchase and sales record ledgers are traceable (practical estimate)
- □ A scanned PDF of the CoC is available for eRIS submission
Regulatory information verified as of October 29, 2026. The parts of this article verifiable in official texts are Articles 20(1) and 23(1) of Proclamation No. 1112/2019 and Section 9.2.3(h) and Annex IV of EFDA-GDL-046; content involving specific technical conditions such as premises area, staffing levels and cold-chain facilities is practical estimate only and must follow the documents currently published by EFDA.
Local resource in Ethiopia: GRZAN supports manufacturers from the Chinese mainland and overseas in engaging with the Ethiopian Food and Drug Authority (EFDA) on market authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent structuring and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical documentation preparation, and the establishment of vigilance and post-market surveillance systems. Service capabilities cover product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), market authorization applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles conformity reasoning, label and instruction-for-use localization in English, and vigilance reporting with field safety corrective action support. Contact: hito.lin@grzan.cn; website www.grzan.cn. For CoC applications, premises readiness and local authorized representative support in the Ethiopian market, GRZAN can also be reached at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us